Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026410 · ClinicalTrials.gov registry record · Phase 1
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Kura Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06026410 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC) that is actively recruiting participants, run by Kura Oncology. The registered enrollment target is 300 participants, roughly in line with the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT06026410, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Kura Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Darlifarnib
- DRUG Cabozantinib
- DRUG Adagrasib
Study Locations (20)
California
- University of Southern California - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Department of Medicine - Los Angeles
Florida
- AdventHealth Celebration - Celebration
- Mayo Clinic Comprehensive Cancer Center - Jacksonville
- Florida Cancer Specialists - Sarasota
Texas
- UT Southwestern Simmons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Mayo Clinic Comprehensive Cancer Center - Phoenix
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06026410
The ClinicalTrials.gov registry entry for NCT06026410 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which Darlifarnib is the first listed.
NCT06026410 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06026410 about?
NCT06026410 is a clinical study titled "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors". This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
What is the current status of trial NCT06026410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2023-10-18. Estimated completion is 2027-04.
What conditions does trial NCT06026410 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer).
What interventions are being tested in trial NCT06026410?
The interventions under investigation include: Darlifarnib (DRUG), Cabozantinib (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06026410?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06026410 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.